When it comes to treating the relapsing-remitting form of Multiple Sclerosis, a wide range of treatments are available including disease modifying drugs and interferon-based medications. While these treatments are effective for the early stages of MS, those with Secondary Progressive MS know from experience that, while these treatments are often tried out on SPMS patients, the results are usually not nearly as effective. Many Secondary Progressive MS patients choose to endure the disease without aid of any treatment.
Currently, researchers are experimenting with different ways to curtail the progression of MS through myelin repair, neural protection, and immunotherapeutics. Among drug developers working on these types of Secondary Progressive MS therapies is Innate Immunotherapeutics.
Find out more about secondary progressive MS.
For those who are in search of new SPMS treatments currently in the drug development pipeline, Innate is a company worth keeping an eye on. Recently, Innate made several headlines regarding their Secondary Progressive MS R&D efforts: back in January, Innate announced that it had raised an additional $10 million in funding for continued testing and research for its experimental MIS416 SPMS drug. Later, the company announced promising clinical trial results for MIS416. While the drug does appear ready for prime time, all indications are that Innate is on to something, with investors and researchers both revealing support for continued research and development.
Because Innate is an Australian-based drug developer, their brand is not quite as exposed in the U.S. Multiple Sclerosis community as some others. MIS416 has never been tested in a U.S. patient population, and the only trial on record for the drug at clinicaltrials.gov has been completed. That being said, the new funding will lead to the next stage of testing for the novel SPMS therapy, and as MIS416 continues to progress through later-stage clinical trials, the therapy’s effectiveness is bound to gain more traction in the U.S. science media and in research circles alike.
In November of 2014, Innate themselves posted a poignant interview with two Secondary Progressive MS patients who had undergone MIS416 treatment. While their symptoms were not completely erased, both patients attest to the effectiveness of the therapy in helping to dramatically improve their quality of life and cognitive function. You can click on the image above to watch the video on YouTube.